Antibody drugs such as monoclonal antibodies (mAb), bispecific antibodies, antibody-drug conjugates (ADCs), and nanobodies garnered increased interest in research and development circles. Sino ...

The engineering and functional characterization of the Fc domain are key to therapeutic antibodies’ efficacy, safety, and pharmacokinetics. The Fc domain is responsible for mediating interactions with ...

The oPool + display platform combines technologies to make and test large numbers of antibodies at once. Antibodies are the critical targeting agents of the immune system and the crux of immune ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In April 2021, the FDA approved the 100th monoclonal ...

Antibodies are a core part of the immune system's pathogen-fighting arsenal, defending the body against bacteria, viruses, and other disease-causing agents. Interestingly, despite antibodies' ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

The history of antibody engineering and production in drug discovery can be traced back to the 1970s and 1980s [1] when scientists first began to explore the potential of using antibodies as ...

You don't want to miss this! To permanently access this eBook for free, fill out the short form below. Developing robust, reproducible antibody pair-based immunoassays is critical for guiding drug ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and rare ...